Aveo pharmaceuticals, inc. (AVEO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net income (loss)

9,388

-5,329

-65,025

-26,887

-

-

-

-

-

-

-

Net loss

-

-

-

-

-15,001

-52,739

-107,029

-114,394

30,648

-58,789

-44,093

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Impairment of property and equipment

-

-

-

-

232

7,600

65

-

-

-

-

Depreciation and amortization

-

-

-

30

9,567

6,219

3,775

2,510

1,654

1,350

1,289

Net loss (gain) on disposal of fixed assets

-

-

-

-

-253

127

-83

-42

-35

-1

-

Stock-based compensation

2,358

2,546

1,089

999

1,132

2,808

3,940

8,007

5,903

4,085

2,387

Non-cash interest expense

567

556

514

465

655

347

-

-

-

-

-

Non-cash change in fair value of PIPE Warrant liability

-11,577

-19,919

33,740

-4,751

-

-

-

-

-

-

-

Non-cash charge for settlement costs (Note 13)

-

-667

2,073

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

285

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-380

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

788

1,434

686

Remeasurement of warrants to purchase convertible preferred stock

-

-

-

-

-

-

-

-

-

713

-333

Amortization of premium and discount on investments

44

-3

-68

-14

-34

-221

-1,041

-2,446

-3,801

-404

-373

Changes in operating assets and liabilities:
Restricted Cash

-

-

-

-

-2,997

-598

-5

2,849

144

-

-

Accounts receivable

-1,395

2,624

-625

-3,614

2,300

1,357

-19,665

13,439

6,819

-96

-1,594

Insurance recovery (Note 13)

-

-15,000

15,000

-

-

-

-

-

-

-

-

Tenant improvement allowance receivable

-

-

-

-

-

-5,833

2,593

3,180

60

-

-

Prepaid expenses and other current assets

742

-774

-684

340

116

-1,503

-3,179

207

1,153

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

3,595

155

Other noncurrent assets

-

-15

-955

827

-96

-50

-31

200

-335

-1,490

1,825

Accounts payable

-2,033

1,063

250

760

-1,820

-993

-6,390

1,724

-343

1,756

3,636

Accrued clinical trial costs and contract research

-574

-2,067

4,323

2,032

-3,562

-1,153

-

-

-

-

-

Other accrued liabilities

-362

240

927

-609

-1,627

-911

-

-

-

-

-

Settlement liability (Note 13)

-

-15,000

15,000

-4,000

4,000

-

-

-

-

-

-

Deferred revenue

-934

1,052

-510

-1,488

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

-7,838

5,254

4,168

2,732

3,981

Deferred revenue

-

-

-

-

2,927

-17,623

-1,293

-1,293

-12,224

-1,900

21,962

Deferred research and development reimbursements

-361

-669

1,123

-

-

-

-

-

-

-

-

Lease exit obligation

-

-

-

-

-5,206

4,981

-

-

-

-

-

Deferred rent

-

-

-

-

-10,569

-9,505

8,672

-

-

-

-141

Deferred rent

-

-

-

-

-

-

-

10,719

-

-

-

Other liabilities

-

-

-

-78

78

0

-

-1,249

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-138

-176

-

Net cash used in operating activities

-2,919

-25,026

-19,164

-31,066

-

-

-

-

26,451

-51,825

-9,973

Investing activities
Purchases of property and equipment

-

-

-

7

22

12,942

3,668

9,948

2,628

1,686

1,734

Net cash used in operating activities

-

-

-

-

-18,230

-54,248

-84,402

-105,729

-

-

-

Purchases of marketable securities

17,917

6,733

34,852

29,421

19,085

42,306

175,391

194,584

376,270

167,706

35,927

Proceeds from maturities and sales of marketable securities

-

25,312

24,450

28,664

11,550

109,767

191,129

339,779

234,795

78,886

41,075

Net cash provided by investing activities

-17,917

18,579

-10,402

-764

-

-

-

-

-144,103

-90,506

3,414

Financing activities
Proceeds from issuance of common stock and warrants, net of issuance costs

25,279

11,471

21,294

14,846

10,218

-

-

-

-

-

-

Proceeds from issuance of common stock and warrants to related parties

5,000

4,500

3,210

525

-

-

-

-

-

-

-

Proceeds from issuance of loan payable and warrants

-

-

5,000

5,000

-

10,000

-

-

-

-

-

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

53,637

-

112,130

136,923

-

Proceeds from issuance of stock for stock-based compensation arrangements

49

494

15

36

268

191

465

1,636

3,237

-

-

Payment of principal of loan payable (Note 6)

3,834

-

-

-

-

-

-

-

-

-

-

Payment of loan maturity fees (Note 6)

300

540

-

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

-

-

-

-

1,241

191

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-6,316

54,710

12,070

135,247

-

-

-

Proceeds from issuance of loans payable

-

-

-

-

-

-

-

3,672

-

-

-

Payments of debt issuance costs

-

-

100

115

-

1,388

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

1,632

159

Principal payments on loans payable

-

-

-

-

11,612

7,785

7,104

2,172

-

-

-

Net cash (used in) provided by financing activities

-

-

-

-

-1,126

1,018

46,998

3,136

-

-

-

Proceeds from refinancing of loans payable

-

-

-

-

-

-

-

-

-

7,555

32,862

Principal payments on loans payable

-

-

-

-

-

-

-

-

-

3,278

1,986

Net cash (used in) provided by financing activities

26,194

15,925

29,419

20,292

-

-

-

-

115,367

142,832

31,035

Net decrease in cash and cash equivalents

5,358

9,478

-147

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-11,538

-25,672

1,480

-25,334

32,654

-2,285

501

24,476

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

26

-26

-

-

-

Supplemental cash flow information
Cash paid for interest

1,971

1,986

2,069

1,539

-

-

-

-

-

-

-

Issuance of warrants

-

-

-

-

-

-

-

-

-

900

-

Conversion of convertible preferred stock

-

-

-

-

-

-

-

-

-

156,856

-

Conversion of preferred stock warrants

-

-

-

-

-

-

-

-

-

745

-

Cash paid for interest

-

-

-

-

1,983

2,018

2,916

3,104

3,016

2,453

2,125

Non-cash operating activity
Non-cash adjustment
Other non-cash activity
Fair value of warrants issued in connection with a class action settlement (Note 13)

-

1,406

-

-

-

-

-

-

-

-

-

Fair value of warrants issued in connection with long term debt

-

-

-

667

-

413

-

-

-

-

-

Fair value of warrants issued in connection with private placement

-

-

-

9,344

-

-

-

-

-

-

-

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

0

0

ASC 606
Increase to deferred revenue due to adoption of ASC 606 - transition adjustment on January 1, 2018

-

2,711

-

-

-

-

-

-

-

-

-